ERBB2 and breast cancer: The publication of the APT trial that successfully de-escalated adjuvant chemotherapy intensity (no doxorubicin or cyclophosphamide) in early stage HER2+ BC has generated interest in de-escalating post-lumpectomy breast irradiation in the same population.